TRML Tourmaline Bio Inc
Price (delayed)
$13.4
Market cap
$344.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.89
Enterprise value
$313.7M
talaris therapeutics is a late-clinical stage biotechnology company based in boston, ma and louisville, ky. talaris is developing transformative cell therapies with the potential to eliminate the burden of chronic
Highlights
The company's debt fell by 41% YoY and by 16% QoQ
TRML's EPS has dropped by 116% since the previous quarter but it has surged by 67% year-on-year
TRML's equity is up by 46% year-on-year but it is down by 7% since the previous quarter
Tourmaline Bio's net income has shrunk by 74% YoY and by 15% QoQ
The quick ratio has contracted by 29% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of TRML
Market
Valuations
Earnings
Shares outstanding
25.69M
Market cap
$344.18M
Enterprise value
$313.7M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$89.73M
Net income
-$73.21M
EBIT
-$73.21M
EBITDA
-$73.02M
Free cash flow
-$77.27M
Per share
Balance sheet
Liquidity
EPS
-$2.89
EPS diluted
-$2.89
Free cash flow per share
-$3.05
Book value per share
$11.7
Revenue per share
$0
TBVPS
$12.19
Total assets
$309M
Total liabilities
$8.95M
Debt
$244,000
Equity
$300.05M
Working capital
$259.93M
Debt to equity
0
Current ratio
30.18
Quick ratio
29.02
Net debt/EBITDA
0.42
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-21.8%
Return on equity
-22.3%
Return on invested capital
-27.1%
Return on capital employed
-24.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRML stock price
How has the Tourmaline Bio stock price performed over time
Intraday
-5.9%
1 week
-20.43%
1 month
2.37%
1 year
-38.53%
YTD
-33.93%
QTD
-11.9%
Financial performance
How have Tourmaline Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$89.73M
Net income
-$73.21M
Gross margin
N/A
Net margin
N/A
Tourmaline Bio's operating income has plunged by 98% YoY and by 14% from the previous quarter
Tourmaline Bio's net income has shrunk by 74% YoY and by 15% QoQ
Growth
What is Tourmaline Bio's growth rate over time
Valuation
What is Tourmaline Bio stock price valuation
P/E
N/A
P/B
1.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
TRML's EPS has dropped by 116% since the previous quarter but it has surged by 67% year-on-year
TRML's equity is up by 46% year-on-year but it is down by 7% since the previous quarter
The price to book (P/B) is 24% lower than the last 4 quarters average of 1.6
Efficiency
How efficient is Tourmaline Bio business performance
TRML's return on invested capital is up by 34% year-on-year and by 7% since the previous quarter
Tourmaline Bio's ROE has increased by 13% YoY but it has decreased by 6% from the previous quarter
The company's return on assets rose by 10% YoY but it fell by 6% QoQ
Dividends
What is TRML's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRML.
Financial health
How did Tourmaline Bio financials performed over time
TRML's total liabilities has soared by 70% YoY and by 21% from the previous quarter
The total assets has grown by 47% YoY but it has contracted by 6% from the previous quarter
The company's debt is 100% lower than its equity
TRML's equity is up by 46% year-on-year but it is down by 7% since the previous quarter
The company's debt fell by 41% YoY and by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.